Stock Price
69.30
Daily Change
1.19 1.75%
Monthly
-10.21%
Yearly
-32.89%
Q1 Forecast
66.09

Date Reference Time Actual Consensus Previous
2026-04-23 FY2026Q1 PM 0.89 0.86
2026-02-24 FY2025Q4 PM 1.04 0.95 0.93
2025-10-30 FY2025Q3 PM 0.92 0.83 0.86
2025-07-30 FY2025Q2 PM 1.01 0.95 0.92
2025-04-24 FY2025Q1 PM 0.86 0.83 0.77



Peers Price Chg Day Year Date
Terumo 2,094.00 -0.50 -0.02% -26.11% Mar/26
Olympus 1,432.00 -3.50 -0.24% -29.04% Mar/26
Abbott 104.55 -0.28 -0.27% -20.40% Mar/26
AngioDynamics 11.27 0.05 0.45% 14.65% Mar/26
Anika Therapeutics 14.75 0.19 1.30% -4.84% Mar/26
AtriCure 30.05 0.52 1.76% -12.57% Mar/26
Baxter International 16.67 -0.45 -2.63% -50.53% Mar/26
Becton, Dickinson and Co. 157.37 -0.90 -0.57% -31.19% Mar/26
Boston Scientific 70.18 0.40 0.57% -30.38% Mar/26
Cooper Companies 71.56 0.11 0.15% -15.79% Mar/26

Indexes Price Day Year Date
USND 21408 -521.74 -2.38% 20.24% Mar/26
US2000 2494 -42.76 -1.69% 20.72% Mar/26

Merit Medical Systems traded at $69.30 this Thursday March 26th, increasing $1.19 or 1.75 percent since the previous trading session. Looking back, over the last four weeks, Merit Medical Systems gained 10.21 percent. Over the last 12 months, its price fell by 32.89 percent. Looking ahead, we forecast Merit Medical Systems to be priced at 66.09 by the end of this quarter and at 60.31 in one year, according to Trading Economics global macro models projections and analysts expectations.

Merit Medical Systems, Inc. designs, develops, manufactures and markets medical products for interventional and diagnostic procedures. The Company’s segments include cardiovascular and endoscopy. The cardiovascular segment consists of cardiology and radiology devices, which assist in diagnosing and treating coronary arterial disease, peripheral vascular disease and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, breast cancer localization and guidance, biopsy, interventional oncology and spine devices. The endoscopy segment consists of gastroenterology and pulmonology devices which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. Within its segments, the Company offers products, including peripheral intervention, cardiac intervention, custom procedural solutions, original equipment manufacturer and endoscopy.